Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

Blood

Volumn 132, Issue 13, 2018, Pages 1365-1371

  Pengo, Vittorio ^a   Denas, Gentian ^a   Zoppellaro, Giacomo ^a   Jose, Seena Padayattil ^a   Hoxha, Ariela ^b   Ruffatti, Amelia ^b   Andreoli, Laura ^c   Tincani, Angela ^c   Cenci, Caterina ^d   Prisco, Domenico ^d   Fierro, Tiziana ^e   Gresele, Paolo ^e   Cafolla, Arturo ^f   De Micheli, Valeria ^g   Ghirarduzzi, Angelo ^h   Tosetto, Alberto ⁱ   Falanga, Anna ^j   Martinelli, Ida ^k   Testa, Sophie ^l   Barcellona, Doris ^m   Gerosa, Maria ⁿ   Banzato, Alessandra ^a   more..

^a Thrombosis Center   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g District Hospital   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ SAN BORTOLO HOSPITAL   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^l Hemostasis and Thrombosis Center   (Italy)

^m UNIVERSITY OF CAGLIARI   (Italy)

ⁿ UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 85052248007     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-04-848333     Document Type: Article

References (38)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005;3(6): 1160-1165.
3. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93(6):1147-1152.
4. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
5. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost. 2006;96(3): 337-341.
6. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005; 3(9):1993-1997.
7. Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(4):809-813.
8. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med. 2011;270(2):110-122.
9. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-696.
10. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.
11. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12): 1133-1138.
12. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848-853.
13. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
14. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
15. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1):9-19.
16. Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus. 2016;25(3):301-306.
17. Pengo V, Tripodi A, Reber G, et al; Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Hae-mostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740.
18. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/ Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(5):792-795.
19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2): 377-381.
20. Pengo V, Biasiolo A, Pegoraro C. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol. 2001;88(10): 1214-1216.
21. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094-2106.
22. Pengo V, Cucchini U, Denas G, et al; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antith-rombotic Therapies (FCSA). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009;119(22):2920-2927.
23. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Hae-mostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
24. Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174(1):30-42.
25. US Food and Drug Administration. FDA briefing document, 10 August 2011. Cardiovascular and Renal Drugs Advisory Committee (CRDAC): Xarelto (rivaroxaban) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2011/202439Orig1s000MedR.pdf. Accessed 3 March 2018.
26. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005; 3(3):514-521.
27. Testa S, Tripodi A, Legnani C, et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016; 137:178-183.
28. Cohen H, Hunt BJ, Efthymiou M, et al; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426-e436.
29. Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4(8): e002322.
30. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014;124(4):611-622.
31. Nuri E, Taraborelli M, Andreoli L, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17-24.
32. Belizna C. Hydroxychloroquine as an antithrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14(4):358-362.
33. Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016; 18(12):74.
34. Undas A, Góralczyk T. Direct oral anticoagulants in patients with thrombophilia: challenges in diagnostic evaluation and treatment. Adv Clin Exp Med. 2016;25(6): 1321-1330.
35. Rivaroxaban for patients with antiphospholipid syndrome [NCT02926170]: US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02926170. Accessed 10 March 2018.
36. Apixaban for the secondary prevention of thromboembolism among patients with the antiphospholipid syndrome (ASTRO-APS) [NCT02295475]: US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02295475. Accessed 12 March 2018.
37. Changes (Side-by-Side) for Study: NCT02295475; 19 November 2014 (v1)-21 June 2017 (v8): US National Library of Medicine. https://clinicaltrials.gov/ct2/history/NCT02295475?A=1&B=8&C5Side-by-Side#StudyPageTop. Accessed 12 March 2018.
38. Posch F, Gebhart J, Rand JH, et al. Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Med. 2017; 15(1):54.